ArriVent BioPharma Inc
Research ArriVent BioPharma Inc (AVBP) on Bullrun: market cap USD 808.39M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAVBP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 808.39M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 49.89M
- Free cash flow-USD 39.58M
Valuation Snapshot
latest market cap is USD 808.39M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 166.31M | -USD 160.59M | n/a | -4.32 | USD 45.54M | USD 14.00K | USD 307.22M |
| FY2024 | USD 0 | -USD 80.49M | -USD 70.21M | n/a | -2.56 | USD 74.29M | USD 176.00K | USD 257.65M |
| FY2023 | USD 0 | -USD 69.33M | -USD 55.84M | n/a | -32.38 | USD 150.39M | USD 317.00K | -USD 153.19M |
| FY2022 | USD 0 | -USD 36.91M | -USD 43.63M | n/a | -1.15 | USD 163.37M | USD 139.00K | -USD 85.11M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 808.39M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 830.58M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 897.95M | n/a | n/a | n/a |
About ArriVent BioPharma Inc
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
Related stock research
Other Healthcare stocks
Aardvark Therapeutics Inc (AARD)
Abeona Therapeutics Inc (ABEO)
Acumen Pharmaceuticals Inc (ABOS)
Absci Corp (ABSI)
Arbutus Biopharma Corp (ABUS)
ABVC BioPharma Inc (ABVC)
Acadia Pharmaceuticals Inc (ACAD)
Adicet Bio Inc (ACET)
Achieve Life Sciences Inc (ACHV)
Alpha Cognition Inc (ACOG)
Aclaris Therapeutics Inc (ACRS)
Acrivon Therapeutics Inc (ACRV)
Frequently asked questions
What is ArriVent BioPharma Inc's market cap?
ArriVent BioPharma Inc's market capitalization is USD 808.39M.
What does ArriVent BioPharma Inc do?
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.